Christopher Dinsmore
Corporate Officer/Principal chez Stablix, Inc.
Fortune : 339 260 $ au 31/03/2024
Profil
Christopher Dinsmore's current jobs include Advisor at Wisconsin Alumni Research Foundation and Scientific Advisory at Stablix, Inc. Formerly, Dr. Dinsmore worked as Executive Director-Discovery Chemistry at Merck & Co., Inc. He also served as VP-Medicinal & Computational Chemistry at FORMA Therapeutics, Inc. from 2014 to 2019.
In 2019, he was an Entrepreneur-Residence at Third Rock Ventures LLC.
From 2020 to 2024, he held the position of Chief Scientific Officer at Kronos Bio, Inc.Dr. Dinsmore completed his undergraduate degree at Bowdoin College and obtained a doctorate from the University of Minnesota.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
KRONOS BIO INC
0,43% | 04/01/2024 | 260 969 ( 0,43% ) | 339 260 $ | 31/03/2024 |
Postes actifs de Christopher Dinsmore
| Sociétés | Poste | Début |
|---|---|---|
Stablix, Inc.
 Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Corporate Officer/Principal | - |
Wisconsin Alumni Research Foundation
 Wisconsin Alumni Research Foundation Miscellaneous Commercial ServicesCommercial Services Wisconsin Alumni Research Foundation provides research patenting and licensing services. It helps steward the cycle of research, discovery, commercialization, and investment for the University of Wisconsin. The firm provides its support services for the entire cycle of innovation, from research to invention to investment. The company was founded in 1925 and is headquartered in Madison, WI. | Corporate Officer/Principal | - |
Anciens postes connus de Christopher Dinsmore
| Sociétés | Poste | Fin |
|---|---|---|
| KRONOS BIO, INC. | Chief Tech/Sci/R&D Officer | 16/02/2024 |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Corporate Officer/Principal | 02/06/2020 |
FORMA Therapeutics, Inc.
 FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Corporate Officer/Principal | 01/06/2019 |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Formation de Christopher Dinsmore
| Bowdoin College | Undergraduate Degree |
| University of Minnesota | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| KRONOS BIO, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Health Technology |
Wisconsin Alumni Research Foundation
Wisconsin Alumni Research Foundation Miscellaneous Commercial ServicesCommercial Services Wisconsin Alumni Research Foundation provides research patenting and licensing services. It helps steward the cycle of research, discovery, commercialization, and investment for the University of Wisconsin. The firm provides its support services for the entire cycle of innovation, from research to invention to investment. The company was founded in 1925 and is headquartered in Madison, WI. | Commercial Services |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Commercial Services |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
